The Aurora Extravascular ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest, while avoiding certain risks of traditional, transvenous ICDs because its lead is placed outside the heart and veins, under the breastbone using a minimally invasive approach.

For more than three years, the cardiology team at Baylor Scott & White Heart and Vascular Hospital – Fort Worth has been an active enrollment site for the Amplatzer Amulet LAAO vs. NOAC clinical trial (CATALYST).

Transthyretin, or ATTR, amyloidosis is a rare disease that, if left untreated, can be devasting and fatal to the patient. Fortunately, in the past decade, there have been advancements in specialized therapies targeting this disease that can improve both quality of life and survival. The Advanced Heart and Lung Disease Center at Baylor Scott & White All Saints Medical Center – Fort Worth is one of the first heart centers in Tarrant County to use Vutisiran (administered under the name of Amvuttra), a small inhibiting RNA silencer that targets the transthyretin protein transcription pathway, to treat the condition. Salman Gohar, MD, FACC, medical director of advanced heart failure and mechanical circulatory support at Baylor Scott & White – Fort Worth and Baylor Scott & White Heart and Vascular Hospital – Fort Worth, is on a mission to help physicians identify this disease early, approaching diagnosis through a new lens.

The incidence of mitral valve disease (MVD) is growing as the overall population ages. Mitral valve disease describes the condition when the mitral valve doesn’t work properly, allowing blood to flow back into the left atrium. When this occurs, the heart doesn’t pump enough blood out of the left ventricle to supply the body with oxygen-rich blood. Patients with the condition frequently don’t exhibit any symptoms, while others experience the classic symptoms of heart failure—fatigue, shortness of breath, lightheadedness, weight gain due to fluid retention, increased heart rate and more.

Baylor Scott & White was the first hospital system in North Texas to successfully implant Barostim™ Baroreflex Activation Therapy. This new FDA-approved device uses neuromodulation—the power of the brain and nervous system to improve the symptoms of patients with advanced systolic heart failure. Eligible patients are reviewed by the patient’s advanced heart failure cardiologist and referred to a vascular surgeon who performs the procedure.